Effect of Night-time and Full-time Splinting for Carpal Tunnel Syndrome
Launched by TAMPERE UNIVERSITY HOSPITAL · Nov 23, 2022
Trial Information
Current as of January 22, 2025
Recruiting
Keywords
ClinConnect Summary
The FINCROSS trial is studying how different types of wrist splinting can help people with carpal tunnel syndrome (CTS), a condition that causes pain, numbness, and tingling in the fingers, especially at night. Specifically, the trial will compare wearing a splint only at night to wearing it all day and night, as well as a period with no splinting at all. Researchers want to find out which method is more effective and if using a splint can reduce the need for surgery later on. The study will involve 110 participants in Finland.
To be eligible for the trial, participants must be at least 18 years old and have been diagnosed with CTS for at least three weeks. They should not have had recent surgery or steroid injections for CTS and must be able to understand Finnish. During the trial, participants will wear splints in different ways and perform stretching exercises on their own. The entire study lasts about 24 weeks, followed by a one-year follow-up to see how well the treatments worked. It's important to note that participants should avoid any other treatments for their CTS while in the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Clinically confirmed carpal tunnel syndrome (CTS) of any severity level (diagnostic criteria: numbness, pain or paraesthesia in the median nerve distribution area of wrist and fingers),
- • 2. Symptom duration of CTS for at least 3 weeks,
- • 3. No previous corticosteroid injection or surgery during last 6 months,
- • 4. Aged 18 years or older,
- • 5. Able to complete self-report questionnaires electronically,
- • 6. Able to understand Finnish,
- • 7. Willing to join the study and follow the study protocol instructions,
- • 8. Sign informed consent.
- Exclusion Criteria:
- • 1. Nerve root or plexus disorders that might be causing CTS mimicking symptoms (e.g., cervical radiculopathy, thoracic outlet syndrome, or whiplash associated disorders),
- • 2. Other neurological condition affecting the function of the hand such as Multiple Sclerosis, previous nerve injury,
- • 3. Active Rheumatoid arthritis or any other active inflammatory joint disease affecting the hand,
- • 4. Thenar muscle atrophy,
- • 5. Untreated hypothyroidism,
- • 6. Known allergy to any of the splint materials (self-reported by patient),
- • 7. Long term treatment (over 4 months) for CTS with no response,
- • 8. Any other known reason that could prevent from participation for the study time.
Trial Officials
Teemu Karjalainen
Principal Investigator
Tampere University Hospital
Jarkko Jokihaara
Principal Investigator
Tampere University Hospital
About Tampere University Hospital
Tampere University Hospital (TAYS) is a leading academic medical center in Finland, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, TAYS integrates cutting-edge medical practices with rigorous scientific investigation, focusing on improving patient outcomes and enhancing treatment modalities across various specialties. The hospital collaborates with a network of researchers, healthcare professionals, and academic institutions to foster a multidisciplinary approach to medical research, ensuring that findings are translated into real-world applications for the benefit of patients and the broader healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampere, , Finland
Helsinki, , Finland
Jyväskylä, , Finland
Tampere, , Finland
Jyväskylä, , Finland
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials